Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBig Technologies Regulatory News (BIG)

Share Price Information for Big Technologies (BIG)

Share Price is delayed by 15 minutes
Get Live Data
98.40    1.60 (1.65%)
Bid:
96.20
Ask:
98.60
Spread: 2.40 (2.495%)
Market Cap: £287.55m
BIG Live PriceLast checked at - London Stock Exchange

Intraday Big Technologies Share Chart

Trading Update

22 Jul 2025 07:00

RNS Number : 9351R
Big Technologies PLC
22 July 2025
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Big Technologies plc

("Big Technologies" or "the Company", together with its subsidiaries the "Group")

Trading Update

Big Technologies plc (AIM: BIG), a leading provider of electronic monitoring solutions for criminal justice and remote care, provides the following update for the six months ended 30 June 2025.

Highlights

· Total Group revenues of approximately £24.8m (H1 2024: £26.5m), £26.1m on a constant currency1 basis;

 

· Criminal Justice revenues of approximately £24.5m (H1 2024: £26.2m). Underlying revenue growth of 4% when excluding the Colombia contract;

 

· Other revenues, including Remote Care revenues were flat in the period at £0.3m (H1 2024: £0.3m);

 

· Two new contracts commencing in H2 2025: Northern Ireland Department of Justice and enlarged renewal of Queensland Corrective Services contract;

 

· Adjusted EBITDA2 of approximately £12.5m (H1 2024: £14.3m), which excludes an exceptional foreign exchange loss of £4.0m in relation to US Dollar balances held in anticipation of a potential acquisition; and

 

· Strong balance sheet with net cash of £94.9m.

 

The Group expects to report revenues for the first half of approximately £24.8m (H1 2024: £26.5m). The Group has continued to see a steady increase in demand for its products from Criminal Justice customers with underlying revenue growth of 4% excluding the Colombia contract from H1 2024.

There has been no impact on the Group from US tariffs during the period.

The gross margin remains high at approximately 67.5% (H1 2024: 70%). This represents a small reduction of 0.6% from FY 2024.

Underlying administrative expenses3 were steady with H1 2024 resulting in Adjusted EBITDA of approximately £12.5m in H1 2025 (H1 2024: £14.3m). Adjusted EBITDA excludes an exceptional foreign exchange loss of £4.0m. The Group held a significant cash balance in US Dollars at 31 December 2024 in anticipation of a potential US acquisition in early 2025. With the acquisition not proceeding, the cash has now been repatriated.

The Group retains a robust balance sheet, with net cash increasing from £93.9m at 31 December 2024 to £94.9m at 30 June 2025 (30 June 2024: £92.9m) notwithstanding the impact of the foreign exchange loss on US Dollar balances since repatriated and continuing litigation costs.

BIG expects to release its interim results for the six months ended 30 June 2025 on 30 September 2025.

 

1 Constant currency is calculated by recalculating H1 2025 revenues using prevailing average foreign exchange rates from H1 2024.

2 Adjusted EBITDA excludes share-based payments and adjusting items

3 Underlying administrative expenses excludes share-based payments, adjusting items and the impact of all foreign exchange rate fluctuations

 

 

Ian Johnson, Big Technologies CEO, said:

"Significant progress has been made in establishing a new organisation and management structure to drive growth in our core markets of Criminal Justice and Remote Care. 

The Group remains well-positioned with the financial flexibility to continue to invest in product and market development. The electronic monitoring market continues to experience significant tailwinds, which together with a clear growth strategy and market leading products, places the Group in a strong position to compete for new business globally.

Following the announcement earlier this year regarding the award of the Northern Ireland contract by the Department of Justice, I am delighted to say that the Company is now able to announce that the Group has resecured the Queensland Corrective Services contract. This is a five-year agreement, with the potential for two additional two-year extension periods. The expected total contract value for the initial 5 year period is AUD 22m, and represents an increase of AUD 4.9m from the previous arrangement over the initial period.

I would like to thank our employees, who despite significant disruption during the period, displayed great resilience and continued to maintain momentum in the business. I would also like to thank our shareholders for their continued support and look forward to providing a further update at the time of the Interim results."

 

-Ends-

 

Enquiries

Big Technologies plc

+44 (0) 192 360 1910

Ian Johnson (Chief Executive Officer)

Mike Johns (Chief Financial Officer)

Zeus (Nominated Adviser and Joint Broker)

 +44 (0) 203 829 5000

Dan Bate / Kieran Russell (Investment Banking)

Benjamin Robertson (Equity Capital Markets)

Singer Capital Markets (Joint Broker)

 +44 (0) 207 496 3000

James Moat / James Todd (Investment Banking)

 

About

Big Technologies is a market leader in the remote personal monitoring industry, operating under the trusted 'Buddi' brand. The Company delivers innovative, high-quality solutions that combine advanced hardware and software to support the monitoring of individuals in both the criminal justice and remote care sectors.

Through its integrated technology platform, Big Technologies offers state-of-the-art Electronic Monitoring solutions on a subscription-based, SaaS-like model. This platform is highly flexible and scalable, enabling tailored deployments across diverse use cases and geographies.

The Company's core technologies are designed to meet the evolving needs of governments, agencies, and care providers, ensuring safety, compliance, and peace of mind through reliable, real-time monitoring.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIRDLILFIE
Date   Source Headline
8th Dec 20233:05 pmRNSDirector/PDMR Shareholding
8th Dec 20237:00 amRNSEBT Share Purchase
6th Dec 20232:06 pmRNSEBT Share Purchase
4th Dec 202312:40 pmRNSEBT Share Purchase
20th Nov 202310:58 amRNSEBT Share Purchase
10th Nov 20239:08 amRNSDirector/PDMR Shareholding
8th Nov 20231:48 pmRNSEBT Share Purchase
1st Nov 20231:42 pmRNSEBT Share Purchase
25th Oct 202310:22 amRNSDirector/PDMR Shareholding
24th Oct 20234:57 pmRNSDirector/PDMR Shareholding - Replacement
24th Oct 202312:23 pmRNSDirector/PDMR Shareholding
24th Oct 202311:55 amRNSDirector/PDMR Shareholding - Replacement
23rd Oct 20235:05 pmRNSDirector/PDMR Shareholding
23rd Oct 20235:03 pmRNSEBT Share Purchase
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20239:05 amRNSIncrease in Share Capital
11th Oct 20231:40 pmRNSEBT Share Purchase
10th Oct 202311:40 amRNSEBT Share Purchase
3rd Oct 20237:00 amRNSEBT Share Purchase
28th Sep 20237:00 amRNSEBT Share Purchase
21st Sep 20237:00 amRNSEstablishment of an Employee Benefit Trust
19th Sep 20237:00 amRNSHalf-year Report
4th Aug 20238:57 amRNSStatement re legal claim
18th Jul 20237:00 amRNSIncrease in share capital and director dealing
7th Jun 20237:00 amRNSIncrease in share capital
23rd May 20231:43 pmRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
17th May 20232:10 pmRNSIncrease in Share Capital
26th Apr 20231:40 pmRNS2022 Annual Report and Notice of AGM
21st Apr 202310:27 amRNSDirector/PDMR Shareholding
5th Apr 20231:04 pmRNSDirector/PDMR Shareholding
4th Apr 202312:27 pmRNSDirector/PDMR Shareholding
31st Mar 202312:12 pmRNSIncrease in Share Capital
29th Mar 20237:00 amRNS2022 Preliminary audited results
23rd Mar 20231:01 pmRNSHolding(s) in Company
20th Jan 20237:00 amRNSTrading Statement
8th Dec 202212:38 pmRNSIncrease in share capital
18th Oct 20227:00 amRNSIncrease in share capital
20th Sep 20227:00 amRNSDirector/PDMR Shareholding
20th Sep 20227:00 amRNSDirector/PDMR Shareholding
15th Sep 20227:00 amRNSHalf-year Report
14th Sep 20224:48 pmRNSHolding(s) in Company
13th Sep 20224:36 pmRNSPrice Monitoring Extension
6th Sep 20224:40 pmRNSSecond Price Monitoring Extn
6th Sep 20224:35 pmRNSPrice Monitoring Extension
26th Aug 20224:40 pmRNSSecond Price Monitoring Extn
26th Aug 20224:35 pmRNSPrice Monitoring Extension
1st Aug 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20222:03 pmRNSDirector/PDMR Shareholding
1st Aug 202211:50 amRNSIncrease in share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.